Takeda hands regulatory affairs work to PRA in new deal

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Pharmacology, Clinical trial, Pharmaceutical industry

Takeda will hand regulatory affairs work to PRA Health Sciences under the clinical development services deal announced last night.

The agreement – financial terms of which were not disclosed – will see PRA manage clinical trials of all drugs in Takeda’s pipeline and see around 300 of the Japanese drug manufacturer’s employees join the contract research organization (CRO).

PRA spokeswoman Christine Rogers told us a wide range of clinical development activities have been handed over to the firm adding that “some regulatory affairs will be included, along with all other development-related functions.” She declined to provide additional details.

The firms said the deal will add flexibility and allow Takeda to reduce its costs.

R&D rejig

Takeda has been reorganizing its R&D operations for the past few years.

In July​ the firm said it would accelerate the process by concentrating its drug development efforts in the US and Japan and focusing on drugs for cancer, gastroenterology, central nervous system disorders and vaccines.

Takeda has signed “strategic” deals with CRO before. In 2011, for example it hired Covance and Quintiles.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more